SEC
SlamSEC
SearchBrowseEarnings

GALECTIN THERAPEUTICS INC

Nasdaq:GALT
Pharmaceutical Preparations·NORCROSS, GA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Galectins are a class of proteins that bind specifically to β-galactoside sugars, such as N-acetyllactosamine, which can be bound to proteins by either N-linked or O-linked glycosylation. They are also termed S-type lectins due to their dependency on disulphide bonds for stability and carbohydrate binding.

Revenue
—
Adj. EBITDA
-$38.1M
FY 2024
Net Income
-$41.1M
FY 2024
EPS (Diluted)
-$0.74
FY 2024
Stock Price
$3.09
-2.2%
2026-03-13
52W Range
$1.12 – $7.13
P/E Ratio
-4.2x
Market Cap
$199.2M
Cash
$25.7M
FY 2024
Total Debt
—
Net Cash
$25.7M
Enterprise Value
$173.6M
Debt / EBITDA
0.7x
FY 2024
EV / EBITDA
-4.6x
Employees
—